Form 4: Twist Bioscience CEO Awarded 146,914 RSUs

Twist Bioscience CEO Emily M. Leproust received an award of 146,914 restricted stock units, vesting over 48 months.

Summary

• Emily M. Leproust, CEO and Director of Twist Bioscience Corp (TWST), was awarded 146,914 restricted stock units (RSUs) on November 18, 2025.
• The RSUs will vest at a rate of 1/16th of the total number on each quarterly anniversary of November 20, 2025, over a 48-month period, contingent on her continuous service.
• Following this transaction, Ms. Leproust directly beneficially owns 880,836 shares of common stock.
• The filing also details her existing employee stock options, including 150,879 shares at an exercise price of $8.82, 266,539 shares at $26.66, 131,290 shares at $23.33, and 64,950 performance-based shares at $67.85 that vested on December 19, 2022.

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation event (RSU award) which is generally neutral but can be seen as slightly positive due to long-term incentive alignment.

Positives

• The RSU award aligns the CEO's long-term interests with those of shareholders, incentivizing sustained performance and retention.
• The vesting schedule over 48 months demonstrates a commitment to long-term leadership and company growth.

Negatives

• The future vesting of RSUs and exercise of options could lead to some dilution for existing shareholders over time.

Future Outlook

The RSU award and its vesting schedule indicate a long-term commitment to the company's future performance and the continued service of its Chief Executive Officer.

Industry Context

This is a routine executive compensation filing common across publicly traded companies, particularly in high-growth sectors like biotechnology, where equity awards are a standard component of executive pay to attract and retain talent and align interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: Potential minor dilution over time as RSUs vest and options are exercised, but also benefit from incentivized executive performance.
• Employees: The RSU award to the CEO may set a precedent or reflect the company's overall compensation philosophy, potentially impacting other equity compensation plans.

Next Steps

• The awarded RSUs will vest quarterly over the next 48 months, starting from November 20, 2025, subject to the CEO's continuous service.
• Existing employee stock options will continue to vest and become exercisable according to their respective schedules and expiration dates.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (an RSU award) and does not contain new fundamental information that would alter the investment thesis for Twist Bioscience. It reflects standard practice for incentivizing executive leadership and is unlikely to significantly impact the stock price.

Keywords

Twist Bioscience, TWST, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Emily M. Leproust, Stock Options, Corporate Governance